LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Canada Goose Holdings Inc. (“Canada Goose” or “the Company”) (NYSE:GOOS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether Canada Goose issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557707

VANCOUVER, BC / ACCESSWIRE / August 27, 2019 / Blue Lagoon Resources Inc. (“Blue Lagoon” or “Company”) (CSE: BLLG) is pleased to announce that, further to the news releases dated August 6, 2019 and August 19, 2019, the Company has completed the acquisition of all of the issued and outstanding shares of ASIC Mining Inc. from its shareholders in consideration for a total of 11,600,000 post-split common shares of the Company. ASIC is a private Canadian company that holds an option to acquire a 100% interest in the Pellaire gold property located in the Clinton Mining Division of British Columbia.

The Company is also pleased to announce that it has completed the 4:1 share split of its issued and outstanding shares. Each shareholder of record of the Company as of the close of business on August 26, 2019 will receive, by mail, three (3) additional shares for each share held on such date.

For further information, please contact:

Rana Vig
President and Chief Executive Officer
Telephone: 604-218-4766
Email: ranavig@gmail.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the completion of the acquisition of ASIC. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “believes”, “plans to”, “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on information as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, to be different, including due to: the receipt of all necessary regulatory approvals, the ability to conclude the Share Exchange, capital expenditures and other costs, and financing and additional capital requirements. Readers should not place undue reliance on forward-looking statements and forward looking information. Blue Lagoon does not undertake to update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE: Blue Lagoon Resources Inc.

ReleaseID: 557709

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reckitt Benckiser Group plc (“Reckitt” or “the Company”) (OTC PINK:RBGLY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s American Depository Shares (“ADSs”) between July 28, 2014 and April 9, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 13, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Reckitt and its senior executives developed a scheme to mislead both investors and the public about its Suboxone Film product, including health and safety risks. This scheme also facilitated the abuse of opiates by U.S. consumers. As part of the scheme, Reckitt touted the safety of the Suboxone Film product while falsely constructing safety concerns about traditional Suboxone tablets. Reckitt’s scheme enriched the company by more than $3 billion, but eventually resulted in investigations by both the DOJ and the FTC. Reckitt settled the investigations into Suboxone Film for $1.4 billion in what was called the “largest opioid settlement in US history.” Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Reckitt, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557706

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB (“Oasmia” or “the Company”) (NASDAQ:OASM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 23, 2015 and July 9, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 27, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Oasmia engaged in deceptive and improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD. These improper transactions resulted in millions of Swedish Kronor not accounted for in the Company’s books. Other transactions related to the Company’s patents were also “carried out in a doubtful way.” Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Oasmia, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557705

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of International Flavors & Fragrances Inc. (“International Flavors” or “the Company”) (NYSE:IFF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. International Flavors announced its second quarter 2019 financials on August 5, 2019. The Company lowered its guidance for fiscal year 2019, setting earnings per share expectations at $4.85 to $5.05 per share on annual revenue of $5.15 billion to $5.25 billion. These figures were revised downwards from $4.90 to $5.10 EPS on $5.2 billion to $5.3 billion in revenue. International Flavors also admitted that it had initiated an investigation of improper payments made by its Israeli subsidiary, “operating principally in Russia and Ukraine . . . to representatives of a number of customers.”

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557703

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intelligent Systems Corporation (“Intelligent Systems” or “the Company”) (NYSE American:INS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Aurelius Value published a report on May 24, 2019, alleging that the financial expert on Intelligent Systems’ Audit Committee engaged in improper accounting practices and also alleged the Company’s CEO engaged in many undisclosed related-party transactions. Based on this news, shares of Intelligent Systems fell nearly 11% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557702

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between November 9, 2017 and April 10, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 9, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Helius touted positive results from the clinical trial of its Portable Neuromodulation Stimulator (“PoNS”) device for treatment of traumatic brain injury, but the clinical trial actually did not produce statistically significant positive results on the effectiveness of the treatment. The trial data did not support the Company’s application for regulatory clearance, and the FDA subsequently denied the application due to insufficient supporting data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Helius, investors suffered damages. According to the Complaint, the Company made false and misleading statements to the market. Helius touted positive results from the clinical trial of its Portable Neuromodulation Stimulator (“PoNS”) device for treatment of traumatic brain injury, but the clinical trial actually did not produce statistically significant positive results on the effectiveness of the treatment. The trial data did not support the Company’s application for regulatory clearance, and the FDA subsequently denied the application due to insufficient supporting data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Helius, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557700

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolent Health, Inc. (“Evolent” or “the Company”) (NYSE:EVH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between March 3, 2017 and May 28, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before October 7, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Evolent’s partnership model was built from the ground up to inflate the Company’s revenue with huge fees and management expenses siphoned from operating partners including Passport. The partnership between Passport and Evolent quickly became unsustainable, especially when combined with complicating factors for Passport’s operations in Kentucky. Passport was left on the brink of insolvency due to the Company draining it of employees and money. In fact, Passport was selling itself off in a bidding process to avoid insolvency. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Evolent, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557699

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eagle Bancorp, Inc. (“Eagle” or “the Company”) (NASDAQ:EGBN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between March 2, 2015 and July 17, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 23, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Eagle failed to maintain adequate internal controls and compliance policies. This failure was likely to result in the need for internal investigations by the Company and created a risk of heightened regulatory scrutiny. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Eagle, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com
Brian Schall, Esq.,
Rina Restaino, Esq.,
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557698

LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Curaleaf Holdings, Inc. (“Curaleaf”or “the Company”) (OTCQX:CURLF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA sent a warning letter to Curaleaf on July 22, 2019. The FDA letter stated that the Company was selling several CBD products on its website that were “misbranded drugs,” a violation of the Federal Food, Drug, and Cosmetic Act. Based on this news, shares of Curaleaf fell more than 7% on July 23, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557696